Patents by Inventor Tao Dao
Tao Dao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240109851Abstract: The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.Type: ApplicationFiled: August 1, 2023Publication date: April 4, 2024Inventors: Katrien Brak, Kae M. Bullock, Greg Cizio, Kathy Dao, Darryl D. Dixon, Joshua R. Dunetz, Luke D. Humphreys, Valerie Huynh, Michael A. Ischay, Trevor C. Johnson, Jeffrey E. Merit, Christopher S. Regens, Eric A. Standley, Dietrich P. Steinhuebel, Justin Y. Su, Tao Wu, Marshall D. Young
-
Patent number: 11859015Abstract: This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising heteroclitic peptides derived from the WT-1 protein.Type: GrantFiled: August 31, 2020Date of Patent: January 2, 2024Assignee: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: David A. Scheinberg, Tao Dao
-
Publication number: 20230374140Abstract: The present technology relates generally to compositions that specifically recognize and bind to a NDC80 peptide complexed with a major histocompatibility antigen (e.g., HLA-A*02). The compositions of the present technology are useful in methods for treating NDC80-associated diseases (e.g., cancers) in a subject in need thereof.Type: ApplicationFiled: October 8, 2021Publication date: November 23, 2023Inventors: Martin KLATT, Tao DAO, David A. SCHEINBERG, Zhiyuan YANG, Jianying LIU
-
Patent number: 11505599Abstract: The presently disclosed subject matter provides antigen-binding proteins (e.g., chimeric antigen receptors) and antibodies or antigen-binding portions thereof that bind to a Foxp3 peptide/MHC molecule complex. Such antibodies, fusion proteins and conjugates thereof are useful for inhibiting regulatory T cells and treating cancers.Type: GrantFiled: January 13, 2017Date of Patent: November 22, 2022Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.Inventors: David A. Scheinberg, Tao Dao, Cheng Liu
-
Patent number: 11384144Abstract: The presently disclosed subject matter provides antigen-binding proteins that specifically bind to Preferentially expressed antigen of melanoma (PRAME), including humanized, chimeric and fully human antibodies against PRAME, antibody fragments (e.g., scFv, Fab and F(ab)2), chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen-binding proteins and antibodies bind to a PRAME peptide/HLA class I molecule complex. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of PRAME associated diseases, including for example, breast cancer, ovarian cancer, melanoma, lung cancer, gastrointestinal cancer, brain tumor, head and neck cancer, renal cancer, myeloma, neuroblastoma, mantle cell lymphoma, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML), Non-Hodgkin lymphoma (NHL), and Chronic lymphocytic leukemia (CLL).Type: GrantFiled: November 20, 2017Date of Patent: July 12, 2022Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.Inventors: David A. Scheinberg, Tao Dao, Cheng Liu, Hong Liu, Yiyang Xu, Su Yan
-
Publication number: 20220168408Abstract: This invention provides methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, by administering a combination of WT1 peptides including each of: YMFPNAPYL, RSDELVRHHNMHQRNMTKL, PGCNKRYFKLSHLQMHSRKHTG, SGQAYMFPNAPYLPSCLES, NLMNLGATL, WNLMNLGATLKGVAA, and WNYMNLGATLKGVAA, or cytotoxic T cells induced by the combination of WT1 peptides. The combination of WT1 peptides may be administered to the subject via a WT1 delivery agent, i.e., in peptide form, or in the form of nucleic acids encoding the WT1 peptides, or in the form of immune cells comprising nucleic acids encoding the WT1 peptides, and/or comprising or presenting the WT1 peptides. The WT1 delivery agents or CTLs can be administered to the subject in a single composition (as a heptavalent immunotherapy composition), or multiple compositions, resulting in delivery of all seven WT1 peptides and induction of an immune response against the WT1-expressing cancer.Type: ApplicationFiled: April 10, 2020Publication date: June 2, 2022Inventors: ANGELOS M. STERGIOU, NICHOLAS J. SARLIS, DAVID A. SCHEINBERG, TAO DAO
-
Patent number: 11242405Abstract: Antigen binding proteins specific for an HLA-A2 restricted Ras peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab?)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, and bispecific antibodies incorporating the specificity of the antigen binding region for each peptide are also contemplated by the disclosure. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the disclosure. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.Type: GrantFiled: September 20, 2017Date of Patent: February 8, 2022Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.Inventors: David A. Scheinberg, Tao Dao, Cheng Liu
-
Publication number: 20210332150Abstract: Antigen binding proteins specific for an HLA-A2 restricted Ras peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab?)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, and bispecific antibodies incorporating the specificity of the antigen binding region for each peptide are also contemplated by the disclosure. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the disclosure. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.Type: ApplicationFiled: September 20, 2017Publication date: October 28, 2021Inventors: David A. SCHEINBERG, Tao DAO, Cheng LIU
-
Publication number: 20210163624Abstract: The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.Type: ApplicationFiled: October 30, 2020Publication date: June 3, 2021Applicants: Memorial Sloan Kettering Cancer Center, Eureka Therapeutics, Inc.Inventors: David SCHEINBERG, Tao DAO, Cheng LIU, Su YAN
-
Publication number: 20200392183Abstract: This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising heteroclitic peptides derived from the WT-1 protein.Type: ApplicationFiled: August 31, 2020Publication date: December 17, 2020Inventors: David A. SCHEINBERG, Tao Dao
-
Patent number: 10858444Abstract: The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.Type: GrantFiled: August 6, 2018Date of Patent: December 8, 2020Assignees: Memorial Sloan Kettering Cancer Center, Eureka Therapeutics, Inc.Inventors: David Scheinberg, Tao Dao, Cheng Liu, Su Yan
-
Patent number: 10815273Abstract: This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising heteroclitic peptides derived from the WT-1 protein.Type: GrantFiled: March 13, 2018Date of Patent: October 27, 2020Assignee: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: David A. Scheinberg, Tao Dao
-
Publication number: 20190284262Abstract: The presently disclosed subject matter provides antigen-binding proteins (e.g., chimeric antigen receptors) and antibodies or antigen-binding portions thereof that bind to a Foxp3 peptide/MHC molecule complex. Such antibodies, fusion proteins and conjugates thereof are useful for inhibiting regulatory T cells and treating cancers.Type: ApplicationFiled: January 13, 2017Publication date: September 19, 2019Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.Inventors: David A. Scheinberg, Tao Dao, Cheng Liu
-
Publication number: 20190144563Abstract: The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.Type: ApplicationFiled: August 6, 2018Publication date: May 16, 2019Applicants: Memorial Sloan Kettering Cancer Center, Eureka Therapeutics, Inc.Inventors: David SCHEINBERG, Tao DAO, Cheng LIU, Su YAN
-
Patent number: 10239952Abstract: Disclosed herein is a bi-specific form of a T cell receptor mimic (TCRm) mAb with reactivity to human immune effector cell antigen and a WT1 peptide/HLA-A epitope. This antibody selectively bound to leukemias and solid tumor cells expressing WT1 and HLA-A as well as activated resting human T cells to release interferon-(IFN-?) and to kill the target cancer cells in vitro. Importantly, the antibody mediated autologous T cell proliferation and directed potent cytotoxicity against fresh ovarian cancer cells. Therapeutic activity in vivo of the antibody was demonstrated in NOD SCID SCID Yc*(NSG) mice with three different human cancers expressing WT1/HLA-A2 including disseminated Ph+ acute lymphocytic leukemia (ALL), disseminated acute myeloid leukemia, and peritoneal mesothelioma. In both of the leukemia xenograft models, mice that received the antibody and T cells also showed longer survival and delayed limb paralysis.Type: GrantFiled: November 7, 2014Date of Patent: March 26, 2019Assignees: Memorial Sloan Kettering Cancer Center, Eureka Therapeutics, Inc.Inventors: David Scheinberg, Jingyi Xiang, Tao Dao, Su Yan, Cheng Liu
-
Patent number: 10040865Abstract: The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.Type: GrantFiled: November 30, 2016Date of Patent: August 7, 2018Assignees: Memorial Sloan Kettering Cancer Center, Eureka Therapeutics, Inc.Inventors: David Scheinberg, Tao Dao, Cheng Liu, Su Yan
-
Publication number: 20180208626Abstract: This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising heteroclitic peptides derived from the WT-1 protein.Type: ApplicationFiled: March 13, 2018Publication date: July 26, 2018Inventors: DAVID A SCHEINBERG, Tao Dao
-
Publication number: 20180148503Abstract: The presently disclosed subject matter provides antigen-binding proteins that specifically bind to Preferentially expressed antigen of melanoma (PRAME), including humanized, chimeric and fully human antibodies against PRAME, antibody fragments (e.g., scFv, Fab and F(ab)2), chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen-binding proteins and antibodies bind to a PRAME peptide/HLA class I molecule complex. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of PRAME associated diseases, including for example, breast cancer, ovarian cancer, melanoma, lung cancer, gastrointestinal cancer, brain tumor, head and neck cancer, renal cancer, myeloma, neuroblastoma, mantle cell lymphoma, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML), Non-Hodgkin lymphoma (NHL), and Chronic lymphocytic leukemia (CLL).Type: ApplicationFiled: November 20, 2017Publication date: May 31, 2018Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.Inventors: David A. Scheinberg, Tao Dao, Cheng Liu, Hong Liu, Yiyang Xu, Su Yan
-
Publication number: 20180134804Abstract: Antigen binding proteins specific for an HLA-A2 restricted Ras peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab?)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, and bispecific antibodies incorporating the specificity of the antigen binding region for each peptide are also contemplated by the disclosure. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the disclosure. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.Type: ApplicationFiled: September 20, 2017Publication date: May 17, 2018Inventors: David A. SCHEINBERG, Tao DAO, Cheng LIU
-
Patent number: 9919037Abstract: This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising heteroclitic peptides derived from the WT-1 protein.Type: GrantFiled: January 15, 2014Date of Patent: March 20, 2018Assignee: Memorial Sloan Kettering Cancer CenterInventors: David A. Scheinberg, Tao Dao